ClinicalTrials.gg
Sign In
CompletedNCT06614218Updated Oct 15, 2026

MIMS® Retrospective Chart Review

An observational study in Open Angle Glaucoma, sponsored by Sanoculis Ltd. Completed at 1 site in Armenia. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-15.

Sponsored by Sanoculis Ltd · Observational

Updated Oct 15, 2026Now CompletedStart date moved+3 moreGo to Updates ↓
Study type
Observational
Model
Other
Time perspective
Retrospective
Enrollment
34
Ages
40 Years to 85 Years
Sex
All
01

Study summary

This is a post-market clinical follow-up, retrospective chart review of MIMS® surgical procedures conducted during time period between Sep 2023 and April 2025.

02

Conditions studied

  • Open Angle Glaucoma

Browse trials for

Keywords

  • Polypharmacy
  • Intraocular Pressure
  • MIMS
  • Minimally Invasive Glaucoma Surgery
  • MIGS
  • MTMT
  • Trabeculectomy
  • Sclerostomy
03

In context

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 117 are open to participants now.

This study's enrollment of 34 is below the median of 101 across 184 observational studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Sanoculis Ltd is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

The study population consists of subjects of Armenian descent that were treated with the MIMS® Device as a standalone procedure between 27 Sep 2023 and 30 April 2024.

Eligibility criteria

Inclusion Criteria:

  1. Eye treated with MIMS® Device as a standalone procedure
  2. MIMS® surgery was performed between 27 Sep 2023 and 30 April 2024
05

Study design

Observational model
Other
Time perspective
Retrospective
Enrollment
34 participants (actual)
Patient registry
No

Groups and cohorts

  • MIMS Surgery Cohort

    This cohort consists subjects treated with MIMS® Device as a standalone procedure during time period (27 Sep 2023 - 31 May 2025), and with documented post-operative follow-up available in the medical charts.

    Device: Minimally Invasive Micro Sclerostomy

Interventions

  • DeviceMinimally Invasive Micro Sclerostomy

    The MIMS® procedure uses the proprietary MIMS® device, which creates a sclerostomy in the eye.

    Also known as: MIMS

06

What researchers measure

Primary outcomes

  1. Change in IOP from medicated baseline at 12 months post-MIMS® surgery

    Time frame: Medicated baseline at 12 months post-MIMS® surgery

  2. Change in the number of topical IOP-lowering medications from medicated baseline at 12 months post-MIMS® surgery

    Time frame: Medicated baseline at 12 months post-MIMS® surgery

  3. Success rate at 12 months post-MIMS® surgery

    Time frame: 12 months post-MIMS® surgery

07

Study locations

1 site
  • S. Malayan Eye Center
    Yerevan, Armenia
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Sep 2023 to primary completion in Apr 2024, 6 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: start Feb 2025 → Sep 2023, primary completion Jan 2026 → Apr 2024 and completion Jan 2026 → Jul 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2024
First posted
Sep 26, 2024
StartActual
Sep 27, 2023was Feb 2025
Primary completionActual
Apr 25, 2024was Jan 2026
CompletionActual
Jul 30, 2025was Jan 2026
Last update
Oct 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Oct 15, 2026
Start date
Feb 1, 2025→Sep 27, 2023 (actual)
Oct 15, 2026
Primary completion
Jan 1, 2026→Apr 25, 2024 (actual)
Oct 15, 2026
Study completion
Jan 1, 2026→Jul 30, 2025 (actual)
Oct 15, 2026
Enrollment
40 (estimated)→34 (actual)
Oct 15, 2026
Show all 1 update
  1. Oct 15, 2026
    Not yet recruiting→Completed
    Start date Feb 1, 2025→Sep 27, 2023 (now actual)
    Primary completion Jan 1, 2026→Apr 25, 2024 (now actual)
    Study completion Jan 1, 2026→Jul 30, 2025 (now actual)
    Enrollment 40 (estimated)→34 (actual)
    + 6 other changes: verification date, description, design details, contact details, site details and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06614218
Lead sponsor
Sanoculis Ltd
Responsible party
Sponsor
First posted
Sep 26, 2024
Start date
Sep 27, 2023
Primary completion
Apr 25, 2024
Completion
Jul 30, 2025
Last update
Oct 15, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Glaucoma, Open-Angle →

Other studies from this sponsor

Sanoculis Ltd

Start the discussion